Science Corporation implants its vision-restoring chip in its first Stargardt disease patient
Science Corporation implanted its PRIMA vision chip in a first Stargardt disease patient in Sydney.
Science Corporation said it implanted its PRIMA retinal chip in its first Stargardt disease patient in May at Sydney Eye Hospital. During early rehabilitation the patient saw a letter and then read a word using camera glasses and a 2-by-2-millimeter implant. PRIMA is already commercially available in Europe for geographic atrophy. CEO Max Hodak, a Neuralink co-founder, said a larger next-generation implant is planned for human use within a year.
8